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Eur J Vasc Endovasc Surg (2011) 42, S7eS8CommentaryW.R. HiattDepartment of Medicine/Cardiology, University of Colorado School of Medicine & CPC Clinical Research, USATwenty years ago John Dormandy (Professor of Vascular
Surgery from St George’s London) and Gordon Murray
(Professor of Statistics from Glasgow), published a critically
important natural history study in subjects with peripheral
artery disease (PAD) and claudication.1 Their observations
were derived from the placebo group of a clinical trial
testing the cardiovascular effects of ketanserin in symp-
tomatic patients with an ankle-brachial index (ABI) < 0.85.
In that study, the annualized all-cause mortality was 4.3%
and (based on the data provided in the article) the annu-
alized risk of cardiovascular death was 3%, non-fatal
myocardial infarction 1.1%, and stroke 0.9% per year, thus
creating an annual risk of myocardial infarction, stroke and
cardiovascular death of 5.0% per year. At the time, the
systemic cardiovascular risk of patients with lower
extremity PAD was not well appreciated. What is remark-
able is that subsequent studies from a wide variety of
populations have shown very similar risks to those
described 20 years ago.
So what have we learned since publication of “The Fate
of the Claudicant”? While the key determinants of this
heightened cardiovascular risk in PAD have been better
elucidated, the message has, otherwise, not really
changed. However, several recent publications should be
highlighted.
First, the risk of a cardiovascular event in the original
publication was found to be related to cardiovascular risk
factors, as well as hemodynamic disease severity in the
limb. Patients with an ABI <0.50 had a two-fold excess risk
of all-cause mortality compared to those with less severe
disease. More recently, a meta-analysis of a large number
of population studies clearly demonstrated the inverse
relationship between ABI and overall mortality, cardiovas-
cular mortality and major coronary events.2 What isDOI of original article: 10.1016/S0950-821X(05)80676-0.
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<1.00 (while PAD has traditionally been defined as an ABI
<0.90), is increased 4-fold in subjects with an ABI <0.60
and the ABI adds independent predictive value over and
above the Framingham Risk Score.
Second, the number of vascular territories affected also
provides key risk stratification information in PAD. For
example, the risk of a cardiovascular event is increased in
patients with PAD who do not have any other clinical
evidence of coronary or carotid disease. If the patient has
documented PAD and/or coronary artery disease, the risk
increases from 3.1%/year to 5.5% per year. If the patient
also has carotid disease, the risk is higher at 9.2%/year.3
Thus the number of major vascular territories is an impor-
tant determinant of overall ischemic risk.
Third, the clinical stage of the disease is also a critical
factor in that patients who are asymptomatic have the
lowest risk and this risk increases as patients develop more
severe symptoms from claudication to rest pain to ischemic
ulcerations. In recent studies in critical limb ischemia, the
risk of major amputation or death at twelve months is as
high as 50% in patients with open ischemic wounds.4
Fourth, associated risk factors and, in particular,
inflammation can provide independent predictive assess-
ment over and above other clinical and hemodynamic
measures. In particular, an increased CRP provided signifi-
cant risk stratification over the ankle-brachial index.5
Over the past two decades, numerous clinical trials,
natural history studies and other investigations have
largely confirmed the early observations of Dormandy and
Murray. Interestingly, the risk of cardiovascular events
documented twenty years ago has remained largely
unchanged in the modern era of patients with PAD. This
is in sharp contrast to falling risks of ischemic events in
patients with coronary and carotid disease, for whom
a number of effective secondary prevention therapies
have been developed. Thus the observations by Dor-
mandy and Murray shed critical light on the huged by Elsevier Ltd. All rights reserved.
S8 W.R. Hiattischemic risk burden carried by patients with symptomatic
PAD.Twentyyearsof studyhaveconfirmedtheseobservations
and provided key additional insight into the major determi-
nants of risk. What now remains is for us to develop more
effective secondary preventive strategies targeting PAD.References
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